# US 2025/0214965 A1 · Compound as kif18a inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0214965 A1
- Document ID: US20250214965A1
- Status: Published application
- Kind: A1
- Application number: 18/574,103
- Filed: 2022-06-27
- Published: 2025-07-03
- Earliest claimed: 2021-06-25
- Assignees: Hangzhou Innogate Pharma Co., Ltd.
- Applicants: Hangzhou Innogate Pharma Co., Ltd.
- Inventors: Hancheng ZHANG; Congcong CAI; Wei JIA
- Web page: https://patentgrep.com/patent/US20250214965A1

## CPC

- C07D 401/14: containing three or more hetero rings
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 31/4523: containing further heterocyclic ring systems
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 35/00: Antineoplastic agents
- C07D 211/10: with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D 211/70: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 211/72: with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D 221/20: Spiro-condensed ring systems
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 471/08: Bridged systems
- C07F 9/59: Hydrogenated pyridine rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound as a KIF18A inhibitor. Specifically, the present invention provides a compound having a structure as represented by the following formula (I), or an optical isomer, pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate and solvate thereof. The compound can be used for treating or preventing diseases or symptoms associated with the activity or expression amount of KIF18A.

## Claims

### Claim 1

A compound of the following formula (I), or the optical isomers, pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, or solvates thereof:
wherein in the formula (I):
A is selected from —Y—R1; wherein, Y is selected from the bond, —S(O)—, —S(O)2—, —S(O)(NH)—, —S(O)2NRa—, —NRaS(O)2—, —NRaS(O)2NRa—, —P(O)(Rq)—, —P(O)(Rq)NRa—, —NRaP(O)(Rq)—, —P(O)(Rq)O—, —OP(O)(Rq)—, —NRa—, —O—, —S—, —C(O)NRa—, —NRaC(O)—, —C(O)O—, —OC(O)—, —NRaC(O)NRa—, —OC(O)NRa—, —NRaC(O)O—, C2-4 alkenyl, and C2-4 alkynyl; wherein each Ra is independently selected from hydrogen and C1-4 alkyl; each Rq is independently selected from C1-4 alkyl, C3-6 cycloalkyl, and 3- to 6-membered heterocyclyl; or Rq and R1 together with the attached phosphorus atom form optionally substituted 4- to 8-membered ring structure, while the ring structure may additionally contain 0-1 heteroatoms optionally selected from N, O and S;
or A is Formula (Ia):
wherein, “” refers to the site of formula (Ia) which attaches to the remaining fragment of the compound of formula (I);
L is selected from —C(O)NRb—, —NRbC(O)—, —NRbC(O)NRb—, —OC(O)NRb—, —C(O)O—, —OC(O)—, —NRbC(O)O—, —S(O)2NRb—, —NRbS(O)2—, —NRb—, —O—, 3- to 6-membered heterocyclyl, and heteroaryl; wherein each Rb is independently hydrogen or C1-4 alkyl;
B is Formula (Ib) or (Id):
wherein “” refers to the site of formula (Ib) or (Id) which attach to the L in a compound of formula (I);
X1, X2, X3 and X4 are each independently selected from N or CRc; wherein Rc is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkynyl, C1-4 alkoxy, hydroxy, C1-4 haloalkoxy, CN, NRdRd, C3-6 cycloalkyl, and 3- to 8-heterocyclic group; wherein each Rd is independently selected from the group consisting of hydrogen, C1-4 alkyl, and C1-4 haloalkyl;
U is selected from N or CRe; wherein Re is selected from the group consisting of hydrogen, halogen, and C1-4 alkyl;
Z1, Z2 and Z3 are each independently selected from N and CRm; wherein Rm is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, hydroxy, C1-4 haloalkoxy, CN, NRdRd, C3-8 cycloalkyl, and 3- to 8-membered heterocyclyl; wherein, each Rd are as defined above; D is selected from the group consisting of bond, —O—, —S—, NRd—, C1-4 alkyl, and C2-4 alkynyl; G is 3-10 membered saturated or unsaturated cyclic structure, which optionally containing 0, 1 or 2 heteroatoms selected from N, O and S, or optionally substituted by R6 or R7;
R1 is selected from the group consisting of C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 10-membered heterocyclyl; said alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclyl being optionally substituted with one or more groups selected from the group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 haloalkenyl, C2-4 alkynyl, C2-4 haloalkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, ORf, SRf, NRdRd, —OC1-4 alkyl-ORf, —OC1-4 alkyl-NRdRd, —NRdC1-4 alkyl-ORf, —NRdC1-4 alkyl-NRdRd, —C(O)Rg, —C(O)ORf, —OC(O)R9, —C(O)NRdRd, —NRdC(O)Rg, —NRdC(O)NRdRd, —OC(O)NRdRd, —NRdC(O)ORf, —OC(O)ORf, —S(O)2NRdRd, —NRdS(O)2R9, and —NRdS(O)2NRdRd; or said cycloalkyl or heterocyclyl is optionally substituted with =M; wherein, Rf is selected from hydrogen, C1-4 alkyl, and C1-4 haloalkyl; Rg is selected from hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 4- to 8-membered heterocyclyl, aryl, and heteroaryl; M is selected from 0 and CRhRi; wherein, Rh and R1 are each independently selected from hydrogen, halogen, and C1-4 alkyl; wherein the alkyl in Rh or Ri is optionally substituted with one or more groups selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, hydroxy, NRdRd, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, and heteroaryl; or Rh and Ri, together with the carbon atom to which they are attached, form a 3- to -6-membered ring structure optionally containing 0, 1 or 2 heteroatoms selected from N, O and S; each Rd is as defined above;
R2 and R3 are each independently selected from the group consisting of hydrogen, fluorine, and C1-4 alkyl; wherein the alkyl is optionally substituted with one or more groups selected from the group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, hydroxyl, NRdRd, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, and heteroaryl; wherein, each Rd is defined as above;
each R4 is independently selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 alkoxy-C1-4 alkyl, hydroxy, hydroxyl-C1-4 alkyl, C1-4 haloalkoxy, C10.4 haloalkoxy-C1-4 alkyl, and CN;
R6 is selected from -Q-R8; wherein Q is selected from bond, —S(O)—, —S(O)2—, —S(O)(NH)—, —S(O)2NRa—, —NRaS(O)2—, —NRaS(O)2NRa—, —NRa—, —O—, —S—, —C(O)NRa—, —NRaC(O)—, —C(O)O—, —OC(O)—, —NRaC(O)NRa—, —OC(O)NRa—, —NRaC(O)O—, C2-4 alkenyl, and C2-4 alkynyl; where each Ra is as defined above;
R6 and R7 are each independently selected from hydrogen, halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 4- to 8-membered heterocyclyl; or R6 and R7 together with the carbon atom to which they are attached form a 3- to 6-membered ring structure, optionally containing 0, 1, or 2 heteroatoms selected from N, O and S; or R6 and R7 together with the carbon atom to which they are attached form C=T, wherein T is selected from CRjRk; wherein R3 and Rk are each independently selected from the group consisting of hydrogen, deuterium, halogen, and C1-4 alkyl; said alkyl is optionally substituted with one or more group selected from halogen, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, ORf, SRf, and NRdRd; or Ri and Rk together with the carbon atom to which they are attached form a 3- to -6 membered ring structure which optionally contains 0 or 1 heteroatom selected from N, O and S; Rd and Rf are as defined above;
R8 is selected from the group consisting of C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 10-membered heterocyclyl; said alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclyl being optionally substituted with one or more groups selected from the group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, 3- to 6-membered heterocyclyl, CN, ORf, SRf, NRdRd, —OC1-4 alkyl-ORf, —OC1-4 alkyl-NRdRd, —NRdC1-4 alkyl-ORf, —NRdC1-4 alkyl-NRdRd, —C(O)Rg, —C(O)ORf, —OC(O)R9, —C(O)NRdRd, —NRdC(O)Rg, —NRdC(O)NRdRd, —OC(O)NRdRd, —NRdC(O)ORf, —OC(O)ORf, —S(O)2NRdRd, —NRdS(O)2Rg, and —NRdS(O)2NRdRd; or said cycloalkyl or heterocyclyl is substituted by =M; wherein, Rf is selected from hydrogen, C1-4 alkyl, and C1-4 haloalkyl; Rg is selected from hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 4- to 8-membered heterocyclyl, aryl, and heteroaryl; M is selected from O and CRhRi; wherein, Rh and Ri are each independently selected from hydrogen, halogen, and C1-4 alkyl; wherein the alkyl in Rh or Ri is optionally substituted with one or more groups selected from hydrogen, halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, hydroxy, NRdRd, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, and heteroaryl; or Rh and Ri together with the carbon atoms to which they are attached form a 3- to -6-membered ring structure optionally containing 0, 1, or 2 heteroatoms selected from N, O and S; each Rd is as defined above;
p and q are each independently selected from 0, 1, 2, 3, 4, 5 and 6; with the proviso that p and q are not simultaneously 0;
m is selected from 0, 1, 2, 3 and 4;
k and n are selected from 1, 2, 3, 4 and 5;
wherein, each of the above mentioned alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl is optionally and each independently substituted by 1-3 substituents selected from the group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, C2-4 alkynyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, aryl, heteroaryl, CN, NO2, ORf, SRf, NRdRd, C(O)R9, C(O)ORf, C(O)NRdRd, NRdC(O)Rg, NRdS(O)2R9, and S(O)2R9, provided that the chemical structure formed is stable and meaningful; wherein Rd, Rf, and Rg are as defined above;
unless otherwise specified, the aryl is aromatic groups having 6 to 12 carbon atoms; the heteroaryl is 5- to 15-membered (preferably 5- to 12-membered) heteroaromatic groups; and the cyclic structure is saturated or unsaturated cyclic groups with or without heteroatoms.

### Claim 2 (depends on 1)

The compound of claim 1, wherein formula (I) is formula (XIa) or formula (XIb):
wherein the fragment
or fragment
is selected from the following group:
the “” refers to the site of the fragment which attach to the remaining fragment of the formula (XIa) or formula (XIb);
A is a group selected from the group consisting of:
“” refers to the site of A which attach to the remaining fragment of the formula (XIa) or formula (XIb);
X1, X2, X3 and X4 are as defined in claim 1;
fragment
is selected from the group consisting of:
“” indicates the site at which the fragment attach to L; “” indicates the site at which attach to Q; “” indicates the site at which the fragment attach to
fragment
is selected from the group consisting of:
the “” refers to the site at which the fragment
attach to the remaining fragment of the compound of formula (XIa) or formula (XIb);
L is selected from —C(O)NH—, —NHC(O)—, —S(O)2NH—, and —NHS( )2—;
“*” indicates a chiral center.

### Claim 3 (depends on 2)

The compound of claim 2, wherein,
the fragment
or fragment
in formula (XIa) or formula (XIb) is selected from the group consisting of:
the “” refers to the site at which the fragment attach to the remaining fragment of the compound of formula (XIa) or formula (XIb).

### Claim 4 (depends on 2)

The compound of claim 2, wherein,
the fragment
of formula (XIa) is selected from the group consisting of:
the “” refers to the site at which the fragment attach to the remaining fragment of the compound of formula (XIa).

### Claim 5 (depends on 2)

The compound of claim 2, wherein the compound (I) is of formula (XII):
wherein Rj and Rk are each independently selected from the group consisting of hydrogen, deuterium, fluorine, chlorine, bromine, and C1-4 alkyl;
k and n are selected from 1, 2, 3, 4 and 5;
while the remaining groups are defined as in claim 2.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound (I) is of formula (XIII):
k and n are selected from 1, 2, 3 and 4;
A is a group selected from:
“” refers to the site of A at which attach to the remaining fragment of the formula (XIII) compound;
fragment
is selected from the group consisting of:
“” indicates the site at which the fragment attach to A; “” indicates the site where the fragment attach to L;
fragment
is selected from the group consisting of:
“” indicates the site at which the fragment attach to L; “” indicates the site attaching to Q; indicates the site at which the fragment attach to
fragment
is selected from the group consisting of:
“” refers to the site of fragment
which attach to the remaining fragment of the formula (XIII) compound;
L is selected from —C(O)NH—, —NHC(O)—, —S(O)2NH—, and —NHS(O)2—;
“*” indicates a chiral center.

### Claim 7 (depends on 6)

The compound of claim 6, wherein the compound (I) is of formula (XIV):
while the groups are defined as in claim 6.

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound (I) is of formula (XV):
while the groups are defined as in claim 1.

### Claim 9 (depends on 6)

The compound of claim 6, wherein the compound (I) is of formula (XVII):
k and n are each independently selected from 1 and 2;
X1 selected from N, C—H, and C—F;
X2 is selected from N, C—H, C—F, C—CN, and C-Me;
X4 is selected from C—H, C—F, and N;
Z1 is selected from C—H, C—F, and N;
Rc is selected from H, halogen, C1-4 alkyl, and CN;
L is selected from —C(O)NH— and —NHC(O)—;
while the remaining groups are defined as in claim 6.

### Claim 10 (depends on 1)

The compound of claim 1, wherein the compound (I) is of formula (XVIII):
X1 selected from N, C—H, and C—F;
X2 is selected from N, C—H, C—F, C—CN, and C-Me;
X4 is selected from C—H, C—F, and N;
Z1 is selected from C—H, C—F, and N;
Rc is selected from hydrogen, halogen, methyl, ethyl, and CN;
A is a group selected from:
fragment
is selected from the group consisting of:

### Claim 11 (depends on 2)

The compound of claim 2, wherein,
in the formula (XIa) or formula (XIb), fragment A is a group selected from:
“” refers to the site of A which attach to the remaining fragment of the formula (XIa) or formula (XIb);

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound (I) is selected from the following group:
“*” indicates a chiral center.

### Claim 13 (depends on 1)

A pharmaceutical composition, wherein comprises the compound of claim 1, or the optical, tautomer, or a pharmaceutically acceptable salt, prodrugs, deuterated derivatives, hydrate or solvate thereof, and pharmaceutically acceptable carriers.

### Claim 14 (depends on 1)

Use of the compound of claim 1, or the optical isomers, pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates or solvates thereof, wherein in the treatment of disease, disorder or condition associated with the activity or expression amount of KIF18A.

### Claim 15 (depends on 14)

The use of claim 14, wherein the disease, disorder or condition is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, colon cancer, thyroid cancer, embryonal rhabdomyosarcoma, skin granulosa cell tumor, melanoma, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, rectal cancer, bladder cancer, throat cancer, breast cancer, prostate cancer, brain tumor, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, renal cancer, skin cancer, gastric cancer, myeloid leukemia, lymphoblastic leukemia, myeloid leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, monocytic leukemia, polycythemia megalosplenica, multiple eosinophilic leukocytosis syndrome, bone marrow cancer and other solid tumors and hematological tumors, as well as virus infection such as influenza.
